AZD1466 / AstraZeneca, Catalyst Biosci 
Welcome,         Profile    Billing    Logout  
 11 Diseases   0 Trials   0 Trials   8 News 
  • ||||||||||  AZD1466 / AstraZeneca, Catalyst Biosci, anatabine (RCP-006) / Rock Creek Pharma
    Preclinical, Journal:  Nicotine-mediated effects in neuronal and mouse models of synucleinopathy. (Pubmed Central) -  Sep 18, 2023   
    Moreover, when investigating the role of nicotinic acetylcholine receptor (nAChR) signaling in nicotine's neuroprotective effects in iPSC-derived dopaminergic neurons, we observed that while ?4-specific antagonists reduced the nicotine-induced calcium response, ?4 agonists (e.g., AZD1446 and anatabine) mediated similar neuroprotective responses against ?-Syn PFF-provoked neurodegeneration. Our results show that nicotine attenuates ?-Syn-provoked neuropathology in vivo and in a humanized neuronal model of synucleinopathy and that activation of ?4?2 nicotinic receptors might mediate these neuroprotective effects.
  • ||||||||||  methylphenidate tablet / Generic mfg.
    Journal:  Cingulate impairments in ADHD: Comorbidities, connections, and treatment. (Pubmed Central) -  Apr 14, 2020   
    Methylphenidate decreases hyperactivity in aMCC...AZD1446 (ɑ4β2 nAChR agonist) improves the Groton Maze task due to high nAChR in dPCC/RSC engaged in spatial orientation...Thus, ADHD children/adolescents respond impulsively to the significance of stimuli without having cortical inhibition. Finally, controls show negative relationships between aMCC and the default mode network, and ADHD compromises this relationship, showing decreased connectivity between ACC and precuneus/PCC.